Labiotech.eu

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is […]

February 13, 2017 - 2 minutesmins - By Evelyn Warner

More News! 11 Feb 2017

This Musician Plays Piano Duets with a Microorganism

Eduardo Miranda researches, composes and performs contemporary music at the interface of biology, computing and the human mind. Eduardo Miranda, Professor of Computer Music at Plymouth University, is the first person to ever compose and perform a piano piece for a human and a microorganism. To allow the tiny creature to play with him, Miranda […]

February 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Feb 2017

Germany gains Strength in Allergy Immunotherapeutics

Bencard Allergie is developing ultra-short course allergy immunotherapies, backed by a strong growth in its German market. Bencard Allergie is the German subsidiary of Allergy Therapeutics in the UK, which develops allergy vaccines. The German company was the first to market allergoids for allergen-specific immunotherapies. These are proteins modified to be recognized by immune cells while inducing […]

February 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Feb 2017

A Dutch University Hospital has Halted Amyloid Beta Drug Studies

Despite the popularity of amyloid beta-targeting drugs, none have managed to pass late stage clinical trials, prompting UMC Radboud to halt its own studies. In the latest blow to the amyloid beta hypothesis, Radboud University Medical Centre in Nijmegen, the Netherlands, announced that it will no longer continue studies into drugs targeting misfolded amyloid beta. These […]

February 10, 2017 - 3 minutesmins - By Diana Kwon

antivenom shortage biotechnology antibody

News and Trends 10 Feb 2017

Can Biotech make Antivenoms Better and Cheaper with Antibodies?

Recombinant antibodies have yet to be applied to the treatment of snakebites, a neglected tropical ‘disease.’ Researchers from Denmark investigated the technology and cost of this novel approach in biotech. Bites from venomous snakes are a major public health problem in tropical areas, where 2 to 3 million people are affected every year and an estimated 100,000 […]

February 10, 2017 - 3 minutesmins - By Denise Neves Gameiro

More News! 9 Feb 2017

After its First Success, the Virtual Biotech Team is Back at it Again

SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

lysogene ipo euronext paris e1486638993948

News and Trends 9 Feb 2017

Gene Therapy Biotech Founded to Save the CEO’s Daughter Goes Public in France

Lysogene has raised €22.6M from its IPO on Euronext Paris that will contribute to the completion of clinical trials to treat the rare genetic diseases. Karen Aiach, CEO of Lysogene, started the company back in 2009 to develop a life-saving treatment for her daughter Ornella with Sanfilippo A. This rare genetic disease severely affects the nervous system of […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Feb 2017

Alma Bio Therapeutics is Aiming to Revolutionize the Treatment of IBD

A new immune modulator to treat Inﬂammatory Bowel Diseases (IBD) is the lead asset in development at Alma Bio Therapeutics. We had the opportunity to meet up with the company’s co-founder and CEO, Binah Baum, to hear more about their fresh approach to treating IBD and other autoimmune diseases. Binah Baum, another female leader in […]

February 9, 2017 - 6 minutesmins - By External Contributor

Atriva Therapeutics seed funding Influenza

News and Trends 8 Feb 2017

German Biotech gets Seed Funding to Repurpose Cancer Drugs for the Flu

Atriva Therapeutics has received seed funding to advance the development of a better therapy for influenza in patients at high risk. Atriva Therapeutics was founded in Tübingen, Germany in 2015 with a quite particular aim: repurposing cancer drugs to treat influenza. Two private investors, the Dutch Stichting Participatie Atriva and the German High-Tech Gründerfonds (HTGF) have contributed with […]

February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 8 Feb 2017

The First Stroke Drug in Decades? French Biotech gets closer to the Clinic

Acticor Biotech has raised €1.5M from CapDecisif Management, which will help its candidate for acute ischemic stroke enter Phase I trials. Acticor Biotech is a spin-off from the French National Institute of Health and Medical Research (Inserm) focusing on treating the acute phase of ischemic stroke, which occurs within the first few hours. The French VC firm CapDecisif Management has seen promise in […]

February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 8 Feb 2017

The FDA lays down Laws of Interchangeability: New Era for Biosimilars?

The new guidelines from the FDA on interchangeability may bring the US biosimilar market up to speed and a new opportunity for European companies. Though the US has long been seen as the most promising market for biosimilars due to the size of the market and high drug prices driving an interest in more affordable options, […]

February 8, 2017 - 4 minutesmins - By External Contributor

gw pharmaceuticals brain tumor cannabinoid

News and Trends 7 Feb 2017

Cannabinoid Drug Prolongs the Life of Brain Tumor Patients in Phase II Trials

GW Pharmaceuticals announced Phase II results for a cannabinoid drug combination with the potential to increase life expectancy in patients with an aggressive form of brain cancer. GW Pharmaceuticals, one of the coolest biotechs in Cambridge, is developing cannabinoid drugs. Its lead candidate, Epidiolex, could reach the market soon and help treat drug-resistant forms of […]

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

This Musician Plays Piano Duets with a Microorganism

Germany gains Strength in Allergy Immunotherapeutics

A Dutch University Hospital has Halted Amyloid Beta Drug Studies

Can Biotech make Antivenoms Better and Cheaper with Antibodies?

After its First Success, the Virtual Biotech Team is Back at it Again

Gene Therapy Biotech Founded to Save the CEO’s Daughter Goes Public in France

Alma Bio Therapeutics is Aiming to Revolutionize the Treatment of IBD

German Biotech gets Seed Funding to Repurpose Cancer Drugs for the Flu

The First Stroke Drug in Decades? French Biotech gets closer to the Clinic

The FDA lays down Laws of Interchangeability: New Era for Biosimilars?

Cannabinoid Drug Prolongs the Life of Brain Tumor Patients in Phase II Trials

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!